These studies involve higher doses than what's currently approved and available for diabetes
Mounjaro is a newer medication that acts on both GLP-1 and GIP receptors, making it more effective than Ozempic for weight loss and blood sugar control in some patients
Some compounding pharmacies add it to semaglutide formulations to enhance fat metabolism alongside the appetite suppression and metabolic effects of the GLP-1 agonist itself
Carbapenemase-producing Klebsiella pneumoniae: molecular and genetic decoding
Both the pen and vial come in 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, and 15 mg doses
To put that into perspective, Ozempic and Wegovy are GLP-1 receptor agonists, while Zepbound and Mounjaro are dual GIP/GLP-1 receptor agonists